A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)
Phase: Phase II-III clinical trials
Principal Investigator: Dott.ssa Verzoni Elena
Main Facility: Oncologia Medica Genitourinaria
Drug: Saruparib (AZD5305)
Pathologies: Prostate tumors
The purpose of the study is to evaluate the impact on metastases-free survival with the addition of saruparib versus placebo to a standard RT + ADT regimen in men with high-risk and very high-risk (localised/locally advanced) prostate cancer with a BRCAm.
Study details include:
- The study will be performed in approximately 300 centres in approximately 26 countries (including the US, EU, China, and Japan)
- The enrolment period will be up to approximately 56 months
- Participants must be eligible for randomisation within 10 months of initial diagnosis (either de novo or BCR)
- The study treatment duration with saruparib/placebo will be 24 months
- The visit frequency during the treatment period will be every 4 weeks.
Randomised participants will continue treatment with saruparib/placebo in combination with ADT until disease progression, unacceptable toxicity occurs, or if the participant requests to stop the study intervention.
Last update: 21/04/2026